

FORM 51-102F3

MATERIAL CHANGE REPORT UNDER NATIONAL INSTRUMENT 51-102

1. **Name and Address of Company**

CB2 Insights Inc. (the “**Company**”)
5045 Orbitor Drive, Building 11, Unit 300
Mississauga, Ontario, L4W 4Y4

2. **Date of Material Change**

January 29, 2019

3. **News Release**

A news release with respect to the material change referred to in this report was disseminated through GlobalNewswire on January 27, 2020 and filed on the system for electronic document analysis and retrieval (SEDAR).

4. **Summary of Material Change**

CB2 Insights Appoints Healthcare Industry Expert and Former IQVIA Executive Tom Brogan to its Board of Directors

5. **Full Description of Material Change**

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“**CB2**” or the “**Company**”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, is pleased to announce the appointment of Tom Brogan, as an independent director to CB2’s Board of Directors. Effective immediately, Mr. Brogan will replace outgoing Directors, David Danziger and Gerry Goldberg, who wish to pursue other opportunities. Current Independent Director, Norton Singhavon has immediately been appointed Interim Chairman of the Board.

Mr. Brogan brings 40 years experience in aggregating anonymized healthcare data to create insights to support traditional pharmaceutical companies and for use in health economic studies. His innovations include a long list of applications that merge Real World Evidence with traditional healthcare protocols. Mr. Brogan is currently the CEO and Chairman at Vestrum Health, an electronic healthcare record data company which delivers information systems to pharmaceutical manufacturers, physician practices and other healthcare stakeholders. Prior to Vestrum Health, he was the founder of Brogan Consulting, which was acquired by IMS in 2010, now IQVIA, one of the world’s largest Contract Research Organizations (CROs), following which Mr. Brogan continued on with the company as Vice President of Global Oncology at IMS Health.

“Mr. Brogan’s extensive experience in building innovative data-driven healthcare technology companies combined with global operations exposure in the Life Sciences sector with leading names in Contract Research and Data Analytics, will be key addition to our Board and leadership team, fostering the growth of CB2,” said Prad Sekar, CEO of CB2 Insights “As we continue to bolster our Board to be representative of the vision and direction of the Company, we are confident that Mr. Brogan’s track record will provide CB2 with exceptional perspective in maximizing our strategies, and exposure to traditional pharma partners for future commercialization.”

“I look forward to being part of the CB2’s leadership team and advising the Company through the next growth phase,” said Tom Brogan. “As I have experienced before, the Company’s unique business strategy is proving it will

a be a critical contributor to advancing the use cannabinoid-based medicines into traditional healthcare through technology, data, and supporting clinical trials – an area that is lacking in the current market.”

“On behalf of the entire Board, I would like to thank Mr. Danziger and Mr. Goldberg for their contributions to the organization” said Norton Singhavon, Interim Chairman of the Board of CB2 Insights. “We are pleased to welcome Mr. Brogan to the Board and look forward to the extensive knowledge and expertise he adds to CB2”. The Company thanks Mr. Danziger and Mr. Goldberg for their contributions made during their tenures.

6. **Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

7. **Omitted Information**

Not applicable.

8. **Executive Officer**

For further information, contact Prad Sekar, CEO of CB2 Insights Inc. at 1-855-874-4999.

9. **Date of Report**

February 24, 2020